

1 **Antiviral activity of aged green tea extract in model food**
2 **systems and under gastric conditions**

3
4 **Irene Falcó^{1,2}, Walter Randazzo^{1,2}, Jesús Rodríguez-Díaz^{1,3}, Roberto Gozalbo-**
5 **Rovira^{1,3}, Daniel Luque⁴, Rosa Aznar^{1,2}, Gloria Sánchez^{2,*}**

6
7 ¹Department of Microbiology and Ecology, University of Valencia. Av. Dr. Moliner,
8 50. 46100 Burjassot. Valencia. Spain

9 ²Department of Preservation and Food Safety Technologies, IATA-CSIC, Avda.
10 Agustin Escardino 7, 46980 Paterna, Valencia, Spain

11 ³Institute for Clinical Research of the Hospital Clínico Universitario (INCLIVA),
12 Valencia, Spain

13 ⁴Unidad de Microscopía Electrónica y Confocal Centro Nacional de Microbiología –
14 ISCIII, Majadahonda, Madrid, Spain

15
16
17
18
19
20
21 ***Corresponding author:**

22 Gloria Sánchez. Department of Preservation and Food Safety Technologies (IATA-CSIC). Av.
23 Agustín Escardino 7. 46980 Paterna. Valencia. Spain.

24 Tel.: + 34 96 3900022; Fax: + 34 96 3939301; E-mail: gloriasanchez@iata.csic.es

26 **Abstract**

27 Aged-green tea extract (GTE) is known to reduce the infectivity of hepatitis A virus
28 (HAV) and murine norovirus (MNV), a human norovirus surrogate, *in vitro* and in
29 washing solutions. Initially, the effect of aged-GTE was evaluated on virus like particles
30 (VLPs) of human norovirus (HuNoV) genogroup I (GI) by a porcine gastric mucine
31 (PGM)-enzyme-linked immunosorbent assay (ELISA) and transmission electron
32 microscopy (TEM), and on HuNoV GI suspensions by an *in situ* capture-RT-qPCR
33 method, suggesting that HuNoVs are very sensitive to aged-GTE treatment at 37 °C.
34 Moreover, the potential application of aged-GTE was evaluated using model foods and
35 simulated gastric conditions. Then, aged-GTE samples prepared in orange juice, apple
36 juice, horchata, and milk, respectively, were individually mixed with each virus and
37 incubated overnight at 37 °C. Aged-GTE at 5 mg/ml in apple juice reduced MNV
38 infectivity to undetectable levels and from 1.0 to 1.8 log in milk, horchata and orange
39 juice. Aged-GTE at 5 mg/ml in orange juice, apple juice, horchata and milk reduced
40 HAV infectivity by 1.2, 2.1, 1.5, and 1.7 log, respectively. Additionally, aged-GTE at 5
41 mg/ml in simulated intestinal fluid reduced MNV titers to undetectable levels and
42 reduced HAV infectivity by ca. 2.0 log. The results show a potential for aged-GTE as a
43 suitable natural option for preventive strategies for foodborne viral diseases.

44

45 **Keywords:** Hepatitis A virus; human norovirus; simulated gastric fluid; green tea
46 extract; food model systems

47

48

49

50

51 **1. Introduction**

52 Foodborne pathogens are a matter of increasing concern to consumers, regulatory
53 bodies, and the food industry (WHO, 2015). Food is, in fact, a vehicle for the
54 transmission of disease agents, most notably pathogenic bacteria and enteric viruses.
55 Epidemiologically significant foodborne viruses include human noroviruses (HuNoV),
56 hepatitis A virus (HAV), and hepatitis E virus (HEV) among others (EFSA, 2016, 2017;
57 WHO, 2015). Globally, it is estimated that foodborne pathogens cause 600 million
58 foodborne illnesses annually, mainly due to infectious agents causing diarrheal diseases
59 (550 million), with HuNoVs being responsible for 120 million cases attributed to food
60 and water (WHO, 2015). For most of these viruses there are no licensed antivirals.
61 Consequently, there is an urgent need for foodborne virus therapeutics, particularly for
62 HuNoV. In this sense, there is a great interest in moving towards natural antiviral and
63 antimicrobial compounds. Natural plant extracts potentially have multiple
64 functionalities, not only to increase the safety and enhance the quality of food products,
65 but also to act as natural antivirals (reviewed by D'Souza (2014)). Over the last two
66 decades, a great deal of effort has been directed toward identifying natural products,
67 mainly of plant origin, to control foodborne viruses. For instance, several natural
68 compounds have been reported to exhibit virucidal activity and have been evaluated
69 against HuNoV surrogates (Li et al., 2013; Ryu et al., 2015). However, even if many
70 natural compounds have already been characterized for their antiviral activity, limited
71 information is available for their use in food applications (Fabra et al., 2016; Li et al.,
72 2012; Sanchez et al., 2015). Additionally, reports on the antiviral activity of natural
73 plant extracts within model food systems and under simulated gastric conditions are still
74 limited (Joshi et al., 2015) .

75 Green tea extract (GTE), from *Camellia sinensis L.*, has demonstrated antiviral effects
76 against murine norovirus (MNV), a human norovirus surrogate, and HAV at 25 °C and
77 37 °C *in vitro* and in food applications (Falcó et al., 2018; Marti et al., 2017; Randazzo
78 et al., 2017). GTE contains large amounts of catechins which contribute greatly to its
79 health benefits (Yilmaz, 2006); (Steinmann et al., 2013). Additionally, recent studies
80 showed that the activity of epigallocatechin-3-gallate (EGCG) and GTE against enteric
81 viruses is due to catechins derivatives; thus, the antiviral activity of GTE is enhanced by
82 preparing the GTE solution 24 h before its use (aged-GTE) (Falcó et al., 2018).
83 However, for GTE to be used as a therapeutic antiviral agent, its effectiveness in
84 complex food matrices and gastrointestinal fluids that mimic digestion needs to be
85 further explored.

86 In the present work, the antiviral activity of aged-GTE was initially assessed against
87 virus-like particles (VLPs) of HuNoV. VLPs are morphologically and antigenically
88 similar to the native infectious viruses and have been previously used to determine the
89 antiviral activity of natural compounds (Li et al., 2012; Liu et al., 2018). HuNoV VLPs
90 were treated with aged-GTE and analyzed by porcine gastric mucine (PGM)-ELISA
91 binding assay and transmission electron microscopy (TEM). Furthermore, the effect of
92 aged-GTE on HuNoV was evaluated by *in situ* capture RT-qPCR (ISC-RT-qPCR).
93 Finally, antiviral activity of aged-GTE was evaluated in four food model systems and
94 under simulated gastric conditions.

95

96 **2. Materials and Methods**

97 **2.1. Clinical sample, virus propagation and cell lines**

98 Fecal sample containing HuNoV genogroup I genotype 4 (kindly provided by Dr. J.
99 Buesa, University of Valencia, Spain) was suspended (10%, wt/vol) in PBS containing

100 2 M NaNO₃ (Panreac, Barcelona, Spain), 1% beef extract (Conda, Madrid, Spain), and
101 0.1% Triton X-100 (Fisher Scientific) (pH 7.2), vortexed and centrifuged at 1000 × g
102 for 5 min. The supernatant was stored at −80 °C in aliquots.
103 MNV-1 (kindly provided by Prof. H. W. Virgin, Washington University School of
104 Medicine, USA) and HAV, strain HM-175/18f (purchased from ATCC VR-1402) were
105 propagated and assayed in RAW 264.7 (kindly gifted by Prof. H. W. Virgin) and FRhk-
106 4 cells (provided by Prof. A. Bosch, University of Barcelona, Spain), respectively. Cell
107 lines and virus stocks were propagated as previously described (Randazzo et al., 2017).
108 Infectious viruses were enumerated by determining the 50% tissue culture infectious
109 dose (TCID₅₀) in 96-well microtiter plates with eight wells per dilution and 20 µl of
110 inoculum per well using the Spearman-Kärber method.

111 **2.2. Aged-GTE preparation**

112 GTE powder (Naturex SA, France) was dissolved in PBS (pH 7.2) at 10 mg/ml and
113 stored for 24 h at room temperature (RT) for optimal antiviral activity, (Falcó et al.,
114 2018), from now on referred to as aged-GTE.

115

116 **2.3. Binding of norovirus VLPs to porcine gastric mucine**

117 Recombinant VLPs containing VP1 and VP2 proteins from the Norwalk GI.1 norovirus
118 strain were produced as previously described (Allen et al., 2009). The PGM-ELISA
119 binding assay was performed as described by Carmona-Vicente and collaborators
120 (2016a) with a few modifications. Briefly, microtiter plates (Maxisorb, Life
121 technologies) were coated with 10 µg/well of type III PGM (Millipore-Sigma) in
122 carbonate-bicarbonate buffer pH 9.6 at 37 °C for 1 h and then incubated overnight (ON)
123 at 4 °C. The following steps were performed at 37 °C. Simultaneously, 10 µg/ml VLPs
124 were incubated ON with aged-GTE at 0.5 and 5 mg/ml. ELISA plates were blocked

125 with 3% bovine serum albumin in PBS for 1 h. After washing with PBS with 0.05%
126 Tween 20 (PBST) the VLP-GTE solutions were added to the plates and incubated for 1
127 h. Primary and secondary antibodies were diluted in PBST and incubated for 1 h each.
128 The primary antibody was a rabbit anti-norovirus polyclonal antiserum (pAb)
129 (Carmona-Vicente et al., 2016b) at a dilution of 1:2,000. The anti-rabbit horseradish
130 peroxidase–labeled antibody IgG (Promega) was used as the secondary antibody at
131 1:10,000 dilution. The reaction was developed by the addition of OPD Sigma Fast
132 (3,3',5,5'-tetramethyl-benzidine, Millipore-Sigma). Color development was stopped
133 with 3M H₂SO₄ after 10 min. Absorbance was measured at 450 nm in microplate reader
134 Multiskan FC (Thermo Scientific). After absorbance measurements the signal
135 corresponding to the control VLPs (0 mg/ml GTE) was considered the 100% of the
136 binding and the percentage of the treated VLPs calculated. Each sample was analyzed in
137 triplicate and the mean values and standard deviation (SD) were calculated.

138 **2.4. Transmission electron microscopy**

139 TEM was used to determine any structural and/or morphological changes of HuNoV
140 GI.1 VLPs treated with aged-GTE compared to non-treated VLPs. PBS 7.2 or aged-
141 GTE at 1 and 10 mg/ml was mixed with equal volumes of VLPs at 100 µg/ml to give
142 final concentrations of 0.5 and 5 mg/ml of aged-GTE and 50 µg/ml of VLPs. The
143 mixtures were then incubated ON at 37 °C. The treated VLPs of HuNoV GI.1 were
144 applied to glow-discharged carbon-coated grids and negatively stained with 2 % uranyl
145 acetate. Images were recorded with Gatan 1k CCD camera in a FEI Tecnai 12 electron
146 microscope operated at 120 kV.

147 **2.5. ISC-RT-qPCR**

148 ISC-RT-qPCR was performed as previously reported (Wang and Tian, 2014; Wang et
149 al., 2014) with some modifications. Briefly, each well was coated with 100 µl of PGM

150 (100 µg/ml) in carbonate-bicarbonate buffer (pH 9.6) at 37 °C for 1 h and then
151 incubated ON at 4 °C. Simultaneously, suspensions of HuNoV GI were mixed with
152 aged-GTE at 0.5 and 5 mg/ml ON at 37 °C.
153 After being washed 5 times with 300 µl of PBS containing 0.05% Tween 20 and 0.3%
154 BSA (PBSTB), the wells were blocked with 300 µL of 3% BSA in PBS at 37 °C for 2 h.
155 The wells were washed 5 times with PBSTB, and 100 µl of HuNoV-GTE samples and
156 controls were added to the microplate and incubated at 37 °C for 1 h. HuNoV GI
157 suspensions without aged-GTE treatment or treated at 99 °C for 5 min were used as a
158 positive and negative control, respectively. Finally, after washing 5 times with PBSTB,
159 each well was added with 100 µl of lysis buffer from NucleoSpin® RNA virus kit
160 (Macherey-Nagel GmbH & Co.).
161 Then, viral RNA was extracted using the same kit according to the manufacturer's
162 instructions. RNA samples were analyzed in duplicate by RT-qPCR using the RNA
163 UltraSense One-Step quantitative RT-PCR system (Invitrogen) and the set of primers
164 and probe recommended by the ISO 15216 (ISO 15216-1, 2017) using the LightCycler
165 480 instrument (Roche Diagnostics, Germany). A standard curve for HuNoV GI, was
166 generated by amplifying 10-fold dilutions of viral RNA by RT-qPCR in quintuplicates,
167 and the numbers of PCRU were calculated. Amplification was performed for 1 cycle of
168 55 °C for 1 h, 1 cycle of 95 °C for 5 min, and 45 cycles of 95 °C for 15 s, 60 °C for 1
169 min and 65 °C for 1 min. The quantification corresponding to the control HuNoV
170 suspension (0 mg/ml GTE) was considered the 100% of the binding and the percentage
171 of the treated HuNoVs calculated. Each sample was analyzed in triplicate and the mean
172 values and SD were calculated.

173 **2.6. Effect of aged-GTE on food model systems**

174 MNV and HAV suspensions (ca. 4 log TCID₅₀/ml) were mixed with equal amounts of
175 aged-GTE in orange juice (pH 2.6), apple juice (pH 3.8), “horchata de chufa” (a local
176 drink speciality, with a composition of 83.5% of water, 10% of sugar and 2.2% of fat;
177 pH 6.8) purchased from a local grocery store, or 2% reduced fat milk (Difco, CAS
178 number 2021-04-13). Final concentrations of aged-GTE were 2.5 and 5 mg/ml. Samples
179 were incubated at 37°C ON in a shaker (180 rpm). Then, the effect of aged-GTE was
180 neutralized with DMEM supplemented with 10% fetal calf serum (FCS). Positive
181 controls were MNV and HAV suspensions added with PBS pH 7.2 under the same
182 experimental conditions. Each treatment was run in triplicate. Confluent RAW 264.7
183 and FRhK-4 monolayers in 96-well plates were used to evaluate the effect of aged-GTE
184 on food model systems. Antiviral activity of aged-GTE was estimated by comparing the
185 number of infectious viruses on the aged-GTE treated virus suspensions and
186 suspensions without aged-GTE. The decay of MNV and HAV titers was calculated as
187 $\log_{10} (N_x/N_0)$, where N_0 is the infectious virus titer for untreated samples and N_x is the
188 infectious virus titer for aged-GTE treated samples.

189 **2.7. Effect of aged-GTE under gastric conditions**

190 Determination of the antiviral activity of aged-GTE was assayed on different solutions
191 of simulated digestion fluids. Simulated salivary fluid (SSF; pH 7.0), simulated gastric
192 fluid (SGF; pH 3.0) and simulated intestinal fluid (SIF; pH 7.0) were prepared as
193 previously described by Minekus et al. (2014). A concentration of 10 mg/ml of GTE
194 was dissolved in each fluid and stored for 24 h at RT. Stocks of MNV and HAV with
195 titers ca. 5 log TCID₅₀/mL were mixed in equal proportions in each solution (SSF, SGF
196 and SIF) obtaining a final concentration of 5 mg/mL of aged-GTE. Samples were
197 incubated in a shaker (180 rpm) at 37 °C during 2 minutes for SSF and 2 h for SGF and
198 SIF. Treatments were neutralized by adding DMEM containing 10% FCS. Positive

199 controls were virus suspensions added with PBS and with each simulated digestion
200 fluids without aged-GTE under the same experimental conditions. Infectious viruses
201 were quantified and effectiveness of the treatments was calculated as described above.

202 **2.8. Data analysis**

203 Results from three replicates of the treatments and controls were statistically analysed
204 using ANOVA with STATISTICA software version 10 (StatSoft Inc., Tulsa, OK, USA)
205 and Tukey's test on a completely randomized design. A P value <0.05 was deemed
206 significant.

207

208 **3. Results**

209 **3.1 Effect of aged-GTE on the binding ability of HuNoV VLPs to PGM**

210 In order to explore the effect of aged-GTE on HuNoV, the binding ability of HuNoV
211 VLPs was tested by PGM-binding ELISA after treatment with aged-GTE at 0.5 and 5
212 mg/ml. The results show a significant reduction, close to 50%, in the binding of the
213 VLPs to the PGM after treatment at both aged-GTE concentrations (data not shown).

214

215 **3.2 Effect of aged-GTE on the morphology of HuNoV VLPs**

216 In order to investigate whether the effect of aged-GTE on VLPs is due to the
217 denaturation of viral capsid proteins or to morphological changes, the morphology of
218 HuNoV GI.1 VLPs before and after treatment with aged-GTE was examined by TEM.
219 The untreated samples of VLP presented assemblies with three different morphologies.
220 Most were isometric particles with a diameter of 23 nm (Fig. 1A, black arrow) that were
221 compatible with the icosahedral VLP with a T=1 architecture. A few isometric particles
222 presented a higher diameter of 40 nm that must have corresponded to icosahedral T3
223 VLPs (Fig 1A, white star). A certain background of smaller assemblies that could be

224 associated with capsomers were also observed (Fig 1A, white arrow). Treatment with
225 aged-GTE at 0.5 mg/ml dramatically decreased the number of VLPs observed per
226 microscopic field (Fig. 1B). Interestingly aged-GTE at 5 mg/ml completely abolished
227 the presence of VLPs, as was observed by TEM. The background of the untreated VLPs
228 revealed the presence of smaller capsomers that could have been unassembled VP1
229 dimers (Fig. 1A, white arrow) that were less present in the 0.5 mg/ml aged-GTE
230 treatment, indicating that the aged-GTE was not destructuring the VLPs into VP1
231 dimers but more likely affecting the VP1 structure itself.

232

233 **3.4 ISC-RT-qPCR**

234 Additionally, the binding ability of HuNoV to PGM was tested by ISC-RT-qPCR after
235 treatment with aged-GTE at 0.5 and 5 mg/ml and heating at 99 °C (Fig. 2). Aged-GTE
236 at 0.5 mg/ml reduced the binding of HuNoV GI to PGM approximately 65 %, while
237 aged-GTE at 5 mg/ml and heating completely eliminated HuNoV GI binding.

238

239 **3.5 Antiviral activity of aged-GTE in model food systems**

240 The reduction of MNV and HAV titers in food models after ON incubation with aged-
241 GTE (2.5 and 5 mg/ml) at 37°C is shown in Table 1. Orange juice significantly ($p <$
242 0.05) reduced MNV infectivity by 0.8 log compared to PBS control. Aged-GTE at 2.5
243 mg/ml in horchata, orange juice, and apple juice reduced MNV titers by 1.2, 0.4 and 1.2
244 log, respectively; no significant differences were reported in milk. Aged-GTE at 5
245 mg/ml in milk, horchata, orange juice and apple juice reduced MNV titers by 1.0, 1.9,
246 1.2 log, and to undetectable limits, respectively. Infectivity of HAV treated with aged-
247 GTE at 2.5 mg/ml in milk, horchata, orange juice and apple juice was reduced by 0.9,

248 1.2, 1.0 and 1.2 log, respectively (Table 1) while aged-GTE at 5 mg/ml reduced HAV
249 infectivity by 1.2, 2.1, 1.5, and 1.7 log, respectively.

250

251 **3.6 Antiviral activity of aged-GTE under simulated gastric conditions**

252 Initially, the infectivity of MNV and HAV was evaluated on the three fluids (Fig. 3).

253 The MNV titers were 5.9 ± 0.3 , 5.4 ± 0.1 , and 5.4 ± 0.1 log TCID₅₀/ml and the HAV

254 titers were 4.7 ± 0.1 , 4.5 ± 0.5 , and 4.5 ± 0.0 log TCID₅₀/ml, SSF, SGF and SIF

255 respectively. Aged-GTE at 5 mg/ml prepared in SSF (pH 7.0) reduced MNV infectivity

256 by 0.7 log, while a 1.5 log reduction was reported after 2 min at 37 °C for HAV.

257 Additionally, aged-GTE at 5 mg/ml reduced virus infectivity by 3.1 and 2.2 log for

258 MNV and HAV, respectively, under SGF conditions (pH 3.0, 37 °C, 2 h). Moreover,

259 aged-GTE at 5 mg/ml reduced MNV and HAV infectivity to undetectable levels and by

260 2.0 log, respectively, under SIF conditions (pH 7.0, 37 °C, 2 h).

261 **4. Discussion**

262 GTE and EGCG have been shown to be highly effective in reducing the titers of MNV

263 and HAV at neutral and alkaline pHs, where the antiviral activity was found to be

264 concentration-, temperature- and exposure time-dependent (Falcó et al., 2017; Gómez-

265 Mascaraque et al., 2016; Randazzo et al., 2017). Moreover, a previous study

266 demonstrated that storage of the GTE solutions for 24 h at 25 °C increased the amount

267 of the antiviral active compounds as a consequence of the degradation and

268 epimerization reactions of polyphenols of GTE (Falcó et al., 2017; Falcó et al., 2018).

269 In the present study, for the first time, we evaluated the effects of aged-GTE on VLPs of

270 HuNoVs GI by PGM ELISA and on HuNoV GI suspensions by ISC-RT-qPCR. PGM

271 contains multiple histo-blood group antigens that have been recognized as receptors or

272 co-receptors for HuNoVs (Tian et al., 2005). Our results indicate that 0.5 mg/ml aged-

273 GTE impairs the binding of HuNoVs to histo-blood group antigens (HBGAs) present in
274 PGM in a way similar to that of the higher concentration (5 mg/ml). It can be argued
275 that the PGM-ELISA binding assay shows binding activity of non-VLP noroviral
276 proteins present in the suspensions after aged-GTE treatments, since the P-domains of
277 norovirus VP1 are enough to bind HBGAs (Tan et al., 2004); thus, the PGM ELISA
278 binding assay would probably be underestimating the antiviral effect of aged-GTE.
279 Additionally, TEM analysis showed that aged-GTE caused structural damage to the
280 HuNoV VLPs with an important reduction of structured VLPs at 0.5 mg/ml and total
281 abolition of VLPs at 5 mg/ml.

282 ISC-RT-qPCR based on PGM has been used successfully to estimate the inactivation of
283 HuNoVs treated by heating, high-pressure processing, chlorine and ethanol (Dancho et
284 al., 2012; Wang and Tian, 2014). In parallel, our study indicated that aged-GTE at 5
285 mg/ml abolished HuNoV GI binding to PGM, while at 0.5 mg/ml some viral particles
286 were still able to bind its receptors, suggesting that HuNoV may be very sensitive to
287 aged-GTE treatment. Furthermore, we demonstrated that the ISC-RT-qPCR method
288 could be used to indirectly indicate the infectivity of HuNoV after treatment with
289 natural compounds.

290 Many natural compounds have shown promising antiviral effects when tested *in vitro*;
291 however, when evaluated in food applications (i.e., sanitizing solutions or incorporated
292 in food packaging), the viral inactivation rate was reduced (Li et al., 2012; Randazzo et
293 al., 2017; Sanchez et al., 2015). Thus, the potential application of natural compounds as
294 antivirals needs to be evaluated in model food systems and under gastrointestinal
295 conditions. For both MNV and HAV, aged-GTE significantly reduced ($p < 0.05$) viral
296 infectivity in the four model food systems evaluated, except for MNV in milk treated
297 with aged-GTE at 2.5 mg/ml. Several factors could be responsible for the decrease in

298 efficacy, such as the interaction of the active compounds or the viruses with food
299 matrices, especially the fat, protein, or sugar content (Joshi et al., 2017; Joshi et al.,
300 2015; Li et al., 2012). Apple juice (rich in carbohydrates) and milk (rich in proteins and
301 lipids) have been used as model food systems in some studies that evaluated the
302 efficacy of natural antivirals (Joshi et al., 2017; Joshi et al., 2015). When aged-GTE (5
303 mg/ml) was prepared in apple juice (pH 6.8), MNV titers were reduced to undetectable
304 levels after 24 h and by 1.7 log for HAV. When aged-GTE was prepared in milk, its
305 effectiveness decreased significantly, with only 1 log reduction of HAV and MNV
306 infectivity. These results are in agreement with previous studies (Joshi et al., 2017;
307 Joshi et al., 2015), where blueberry proanthocyanidins (B-PAC) and GSE retained their
308 antiviral activity in apple juice, though their antiviral effect decreased in milk. For
309 instance, aged-GTE (5 mg/ml) prepared in milk reduced MNV titers by 1.0 log (Table
310 1) after 24 h at 37 °C, while B-PAC at the same experimental conditions (5 mg/ml, 24 h,
311 37 °C) decreased MNV titers by 0.8 log (Joshi et al., 2017). For HAV, aged-GTE at 5
312 mg/ml reduced HAV titers by 1.2 log in milk (Table 1) while similar inactivation rates
313 (0.8 log) were reported for GSE at 4 mg/ml tested under the same experimental
314 conditions (Joshi et al., 2015). Although horchata contains 2.2% fat, 5 mg/ml aged-GTE
315 in hochata reduced MNV and HAV infectivity by ca. 2 log, resulting in a potential
316 carrier of natural antivirals.

317 In order to use natural compounds as antivirals, it is particularly important to assess the
318 maintenance of their antiviral activity under conditions encountered during consumption
319 and transition through the gastrointestinal tract. Interestingly, when aged-GTE was
320 added to SSF, SGF, and SIF solutions, significant reductions of MNV and HAV
321 infectivity were recorded. In particular, aged-GTE (5 mg/ml) prepared in SIF reduced
322 MNV infectivity to undetectable levels and by ca. 2 log for HAV (Fig. 3). These results

323 are consistent with the inactivation rates reported for GSE and PAC-B in SIF. GSE
324 prepared in SIF reduced MNV and HAV titers by 1.7 and 1.4 log, respectively (Joshi et
325 al., 2015), while PAC-B prepared in SIF reduced MNV infectivity to undetectable
326 levels (Joshi et al., 2017). Moreover, aged-GTE prepared in SGF (pH 3.0) reduced
327 MNV infectivity to a lesser extent compared to aged-GTE in SIF (pH 7.0). One
328 plausible reason could be derived from the fact that aged-GTE is very effective in
329 inactivating MNV at neutral and alkaline pHs, but less effective at pH 5.5, and this has
330 been correlated to the formation of catechin derivatives (Falcó et al., 2018).
331 Overall, the results of the evaluation of aged-GTE in model food systems and simulated
332 gastric conditions, could help in moving toward the development of sustained-released
333 products containing aged-GTE for consumption. In addition, this study suggests that
334 exposure to intestinal and gastric fluids maintains the antiviral activity of aged-GTE, but
335 future studies should involve animal feeding studies with aged-GTE to determine its
336 antiviral effects.
337 Based on the effects of aged-GTE against MNV and HAV, with reduced effectiveness
338 in model food systems, encapsulation strategies (Falcó et al., 2017; Gómez-Mascaraque
339 et al., 2016) to protect aged-GTE from food matrices may be of great interest for
340 optimal antiviral activity as well as time-released in the intestinal tract.

341

342 **Acknowledgements**

343 This work was supported by the Spanish Ministry of Economy and Competitiveness
344 (MINECO) (RYC-2013-12442) and the Spanish National Institute for Agriculture and
345 Food Research and Technology (INIA) co-financed by the European Social Fund
346 (Project RTA2014-00024-C03). Financial support has been co-sponsored by the
347 European Regional Development Fund. JRD was supported by the “Ramon y Cajal”

348 Young Investigator Grants and WR by a postdoctoral fellowship from Generalitat

349 Valenciana (APOSTD/2018/150).

350

351

352

353 **References**

- 354 Allen, D.J., Noad, R., Samuel, D., Gray, J.J., Roy, P., Iturriza-Gámara, M., 2009.
355 Characterisation of a GII-4 norovirus variant-specific surface-exposed site involved in antibody
356 binding. *Viol. J.* 6.
- 357 Carmona-Vicente, N., Allen, D.J., Rodriguez-Diaz, J., Iturriza-Gomara, M., Buesa, J., 2016a.
358 Antibodies against Lewis antigens inhibit the binding of human norovirus GII.4 virus-like
359 particles to saliva but not to intestinal Caco-2 cells. *Viol. J.* 13, 82.
- 360 Carmona-Vicente, N., Vila-Vicent, S., Allen, D., Gozalbo-Rovira, R., Iturriza-Gomara, M.,
361 Buesa, J., Rodriguez-Diaz, J., 2016b. Characterization of a Novel Conformational GII.4
362 Norovirus Epitope: Implications for Norovirus-Host Interactions. *J. Virol.* 90, 7703-7714.
- 363 D'Souza, D.H., 2014. Phytocompounds for the control of human enteric viruses. *Curr. Opin.*
364 *Viol.* 4, 44-49.
- 365 Dancho, B.A., Chen, H., Kingsley, D.H., 2012. Discrimination between infectious and non-
366 infectious human norovirus using porcine gastric mucin. *Int. J. Food Microbiol.* 155, 222-226.
- 367 EFSA, 2016. The European Union summary report on trends and sources of zoonoses, zoonotic
368 agents and food-borne outbreaks in 2015. *EFSA J.* 14.
- 369 EFSA, 2017. Public health risks associated with hepatitis E virus (HEV) as a food-borne
370 pathogen. *EFSA J.* 15.
- 371 Fabra, M.J., Castro-Mayorga, J.L., Randazzo, W., Lagaron, J.M., Lopez-Rubio, A., Aznar, R.,
372 Sanchez, G., 2016. Efficacy of Cinnamaldehyde Against Enteric Viruses and Its Activity After
373 Incorporation Into Biodegradable Multilayer Systems of Interest in Food Packaging. *Food*
374 *Environ. Virol.* 8, 125-132.

375 Falcó, I., Randazzo, W., Gómez-Mascaraque, L., Aznar, R., López-Rubio, A., Sánchez, G.,
376 2017. Effect of (-)-epigallocatechin gallate at different pH conditions on enteric viruses. *LWT -*
377 *Food Sci. Technol.* 81, 250-257.

378 Falcó, I., Randazzo, W., Gómez-Mascaraque, L., Aznar, R., López-Rubio, A., Sánchez, G.,
379 2018. Fostering the antiviral activity of green tea extract for sanitizing purposes through
380 controlled storage conditions. *Food Control* 84, 485-492.

381 Gómez-Mascaraque, L., Soler, C., Lopez-Rubio, A., 2016. Stability and bioaccessibility of
382 EGCG within edible micro-hydrogels. Chitosan vs. gelatin, a comparative study. *Food Hydroc.*
383 61, 128-138.

384 Joshi, S., Howell, A.B., D'Souza, D.H., 2017. Blueberry proanthocyanidins against human
385 norovirus surrogates in model foods and under simulated gastric conditions. *Food Microbiol.*
386 63, 263-267.

387 Joshi, S., Su, X., D'Souza, D.H., 2015. Antiviral effects of grape seed extract against feline
388 calicivirus, murine norovirus, and hepatitis A virus in model food systems and under gastric
389 conditions. *Food Microbiol.* 52, 1-10.

390 Li, D., Baert, L., Uyttendaele, M., 2013. Inactivation of food-borne viruses using natural
391 biochemical substances. *Food Microbiol.* 35, 1-9.

392 Li, D., Baert, L., Zhang, D., Xia, M., Zhong, W., Van Coillie, E., Jiang, X., Uyttendaele, M.,
393 2012. Effect of grape seed extract on human norovirus GII.4 and murine norovirus 1 in viral
394 suspensions, on stainless steel discs, and in lettuce wash water. *Appl. Environ. Microbiol.* 78,
395 7572-7578.

396 Liu, D., Deng, J., Joshi, S., Liu, P., Zhang, C., Yu, Y., Zhang, R., Fan, D., Yang, H., D'Souza,
397 D.H., 2018. Monomeric catechin and dimeric procyanidin B2 against human norovirus
398 surrogates and their physicochemical interactions. *Food Microbiol.* 76, 346-353.

399 Marti, E., Ferrary-Américo, M., Barardi, C.R.M., 2017. Viral disinfection of organic fresh
400 produce comparing Polyphenon 60 from green tea with chlorine. *Food Control* 79, 57-61.

401 Minekus, M., Alming, M., Alvito, P., Ballance, S., Bohn, T., Bourlieu, C., Carriere, F.,
402 Boutrou, R., Corredig, M., Dupont, D., Dufour, C., Egger, L., Golding, M., Karakaya, S.,
403 Kirkhus, B., Le Feunteun, S., Lesmes, U., Macierzanka, A., Mackie, A., Marze, S.,
404 McClements, D.J., Menard, O., Recio, I., Santos, C.N., Singh, R.P., Vegarud, G.E., Wickham,
405 M.S., Weitschies, W., Brodkorb, A., 2014. A standardised static in vitro digestion method
406 suitable for food - an international consensus. *Food Funct.* 5, 1113-1124.

407 Randazzo, W., Falco, I., Aznar, R., Sanchez, G., 2017. Effect of green tea extract on enteric
408 viruses and its application as natural sanitizer. *Food Microbiol.* 66, 150-156.

409 Ryu, S., You, H.J., Kim, Y.W., Lee, A., Ko, G.P., Lee, S.J., Song, M.J., 2015. Inactivation of
410 norovirus and surrogates by natural phytochemicals and bioactive substances. *Mol. Nutr. Food.*
411 *Res.* 59, 65-74.

412 Sanchez, C., Aznar, R., Sanchez, G., 2015. The effect of carvacrol on enteric viruses. *Int. J.*
413 *Food Microbiol.* 192, 72-76.

414 Steinmann, J., Buer, J., Pietschmann, T., Steinmann, E., 2013. Anti-infective properties of
415 epigallocatechin-3-gallate (EGCG), a component of green tea. *Br. J. Pharmacol.* 168, 1059-
416 1073.

417 Tan, M., Hegde, R.S., Jiang, X., 2004. The P domain of norovirus capsid protein forms dimer
418 and binds to histo-blood group antigen receptors. *J. Virol.* 78, 6233-6242.

419 Tian, P., Brandl, M., Mandrell, R., 2005. Porcine gastric mucin binds to recombinant norovirus
420 particles and competitively inhibits their binding to histo-blood group antigens and Caco-2 cells.
421 *Lett. Appl. Microbiol.* 41, 315-320.

- 422 Wang, D., Tian, P., 2014. Inactivation conditions for human norovirus measured by an in situ
423 capture-qRT-PCR method. *Int. J. Food Microbiol.* 172, 76-82.
- 424 Wang, D., Xu, S., Yang, D., Young, G., Tian, P., 2014. New in situ capture quantitative (real-
425 time) reverse transcription-PCR method as an alternative approach for determining inactivation
426 of Tulane virus. *Appl. Environ. Microbiol.* 80, 2120-2124.
- 427 WHO, 2015. WHO estimates of the global burden of foodborne diseases: foodborne disease
428 burden epidemiology reference group 2007-2015. World Health Organization, Geneva.
- 429 Yilmaz, Y., 2006. Novel uses of catechins in foods. *Trends Food Sci. Technol.* 17, 64-71.
- 430

431 **Table 1.** Murine norovirus (MNV) and hepatitis A virus (HAV) titers (log TCID₅₀/ml)
 432 after treatments with aged-GTE prepared in different model food systems and incubated
 433 overnight at 37 °C. Each treatment was done in triplicate. Within each column for each
 434 model food system, different letters denote significant differences between treatments (p
 435 < 0.05).
 436

Food models	Aged-GTE (mg/ml)	MNV		HAV	
		Recovered titers	Log reduction	Recovered titers	Log reduction
PBS		4.45 ± 0.12 _a	-	4.57 ± 0.13 _a	-
Milk	0	4.41 ± 0.38 _a	-	4.45 ± 0.22 _a	-
	2.5	4.32 ± 0.13 _a	0.08	3.57 ± 0.13 _b	0.88
	5	3.37 ± 0.31 _b	1.04	3.28 ± 0.29 _b	1.17
Horchata	0	4.45 ± 0.22 _a	-	4.52 ± 0.26 _a	-
	2.5	3.20 ± 0.00 _b	1.25	3.32 ± 0.22 _b	1.20
	5	2.57 ± 0.22 _c	1.88	2.37 ± 0.29 _c	2.15
Orange juice	0	3.62 ± 0.19 _b	-	4.08 ± 0.00 _a	-
	2.5	3.20 ± 0.00 _c	0.42	3.07 ± 0.33 _b	1.00
	5	2.45 ± 0.22 _d	1.17	2.62 ± 0.26 _c	1.46
Apple juice	0	4.53 ± 0.33 _a	-	4.28 ± 0.14 _a	-
	2.5	3.20 ± 0.00 _b	1.25	3.07 ± 0.22 _b	1.21
	5	< 1.15 _c	>3.38	2.53 ± 0.07 _c	1.75

437

438

439 **Figure legends**

440

441 **Figure 1.** Representative TEM field showing negatively stained untreated VLPs (A)
442 and VLPs treated with aged-GTE (0.5 mg/ml) (B). The white star indicates a 40 nm
443 putative T3 symmetry VLP. The black arrow points to a 23 nm putative T1 symmetry
444 VLP. The white arrow points to VP1 capsomer. The scale bar indicates 200 nm.

445

446 **Figure 2.** Effect of aged-GTE on the binding of human norovirus GI to PGM analyzed
447 by ISC-RT-qPCR. Each bar represents the average of triplicates.

448 Asterisks show statistical differences ($p < 0.05$)

449

450 **Figure 3.** Reduction of murine norovirus (MNV) (A) and hepatitis A virus (HAV) (B)
451 titers ($\log \text{TCID}_{50}/\text{ml}$) after treatments with aged-GTE (5 mg/ml) prepared in simulated
452 salivary fluid (SSF; 2 min at 37 °C), simulated gastric fluid (SGF; 2 h at 37 °C) and
453 simulated intestinal fluid (SIF, 2 h at 37 °C)

454 *Black: Control (virus in simulated fluids); grey: aged-GTE prepared in simulated
455 fluids

456 **Each column represents the average of triplicates. Each bar represents the average of
457 triplicates. Within each column for each virus, different letters denote significant
458 differences between treatments ($P < 0.05$).

459 Solid line depicts the detection limit.

460